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Patients with Duchenne muscular dystrophy (DMD) are living longer into adulthood due to a variety of improvements in health care practices.
This growing patient population presents new therapeutic challenges. In this article, we review the literature on current treatment of adult DMD as
well as our own experience as a multidisciplinary team actively caring for 23 men ages 19–38 years of age. Approximately one quarter of our
adult DMD patients have remained on moderate dose corticosteroids. Daily stretching exercises are recommended, particularly of the distal upper
extremities. Cardiomyopathy is anticipated, detected, and treated early with afterload reduction. Oxygen saturation monitoring, noninvasive
positive pressure ventilation and cough assist devices are routinely used. Other medical issues such as osteoporosis, gastrointestinal and urinary
symptoms are addressed. Current and future therapies directed at prolonging the lifespan of those with DMD will result in further increases in this
adult population with special needs and concerns. These needs are best addressed in a multidisciplinary clinic.
© 2006 Elsevier B.V. All rights reserved.Keywords: Duchenne muscular dystrophy; Cardiomyopathy; Multidisciplinary clinicDuchenne muscular dystrophy (DMD) has long been
considered a uniformly, fatal childhood disease. While there
were few survivors of DMD beyond teenage years in the 1960s
and 1970s, lifespan has been gradually extended in the past few
decades [1]. With many DMD patients now living into their late
20s and 30s, it is now appropriate to anticipate that a current
child with DMDwill not only reach adulthood but may live well
into his fourth decade. Improvement in survival with current
treatments, and potentially enhanced by future therapies
described in this issue, necessitates that physicians are informed
regarding appropriate care for this emerging population.
Although there is as yet scant data on outcomes, the consensus
is that this care is best delivered by a multidisciplinary team.
This article will review the literature and our experience caring
for adults with DMD in a multidisciplinary clinic.
Patients with DMD are living longer into adulthood from a
variety of factors. These likely include routine flu and
pneumococcal vaccination, aggressive physical therapy and⁎ Corresponding author. Tel.: +1 410 614 4003; fax: +1 410 614 9003.
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doi:10.1016/j.bbadis.2006.06.009early use of antibiotics. Nocturnal ventilation has improved
oxygenation, decreased atelectasis and has had a measurable
effect on reducing morbidity and mortality [1]. Other changes in
practice such as increased spinal surgery, use of afterload
reduction for cardiomyopathy and earlier and prolonged use of
corticosteroids are also likely contributors to increased survival,
but there is currently insufficient data to evaluate their effects.
Corticosteroid use has doubtlessly increased the number of
years of ambulation. However, a correlation between walking
and survival has not been demonstrated [2]. Perhaps one of the
greatest contributors to increased survival for those with DMD
is coordinated, multidisciplinary care.
Due to increasing numbers and specialized needs of adults
with DMD, we have developed a multidisciplinary clinic
dedicated to these patients. Patients were diagnosed by their
pediatric neurologist by muscle biopsy showing lack of
dystrophin immunostaining and/or by genetic mutation analy-
sis. Currently, there are 23 patients with a molecular diagnosis
of DMD actively participating in our adult DMD clinic ranging
in age from 18 to 38 (mean age 24). Nineteen of these patients
are Caucasian, 3 African-American and 1 Asian-American. A
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specialists by concurrent clinics in the same Muscular
Dystrophy Association (MDA) center where adult specialists
are introduced to patients prior to assuming their care and where
records are shared electronically. Patients and families are seen
by a neurologist, pulmonologist, cardiologist, physical and
occupational therapists, care coordinator and where appropriate,
social worker and genetics counselor. Twice yearly visits are
encouraged to keep abreast of changes in health status and to
decrease the number of hospitalizations.
1. Neurologic care
The neurologist acts as orchestrator of services and becomes,
in many instances, the primary medical doctor. Although all
adults with DMD should have identified a pulmonologist and
cardiologist familiar with their disease, the neurologist
coordinates the care of these specialists. For example, as
discussed below, history taken by the neurologist on number of
chest infections and signs of nocturnal hypoventilation is
important in making a collective decision regarding cough and
ventilation assist devices. Similarly, shortness of breath,
peripheral edema and orthopnea are important considerations
for discussion of afterload reduction with the cardiologist.
1.1. Corticosteroids
Glucocorticoid corticosteroids improve muscle strength and
function in children with DMD treated from 6 months to 2 years
as shown in randomized controlled clinical trials [3,4]. The most
effective dose appears to be 0.75 mg/kg/day [5]. Whether to
continue corticosteroids as an adult, and at what dose, is a
decision that the neurologist makes with the patient and family.
The decision is difficult due to known systemic risks of long-
term steroid use and unknown, but potential, benefits to
respiratory and cardiac muscle. The 2006 Cochrane review of
corticosteroid use in DMD could not evaluate long term benefits
from currently published studies [5]. While the conventional
practice several years ago was to discontinue steroids when the
patient began to use the wheelchair full time, many patients are
continuing to use steroids indefinitely with the hopes that it
provides benefit to muscles of respiration. There is some data to
support respiratory benefit as measured by forced vital capacity;
however, these trials were also in children and short term [3,4].
In our adult DMD clinic, we do not initiate patients on
steroids who have chosen not to take steroids or have discon-
tinued them due to side effects or uncertainty of benefit. In adult
patients who have chosen to continue on steroids after loss of
ambulation, we assess the current side effects and if not overly
burdensome, attempt to maintain steroids dosing. Although
long-term steroid use has a host of well described side effects
including weight gain, development of Cushingoid facies, short
stature, hypertension, hyperglycemia, cataracts, and osteoporo-
sis, by far the most common reason patients found to discon-
tinue prednisone was excessive weight gain which inhibited
transfers and care. Practice parameters developed by the Quality
Standards Subcommittee of the American Academy of Neuro-logy recommends decreasing prednisone to 0.5 mg/kg/day if
weight gain >20% over estimated normal weight for height
occurs over a 12-month period with further decrease to 0.3 mg/
kg/day if excessive weight gain continues [6]. Six of our 23
adult DMD patients have continued on low to moderate dose
prednisone but none have been able to tolerate and sustain the
0.75 mg/kg dose that they were originally treated with when
ambulatory. The mean daily dose for those taking prednisone in
our adult clinic is 0.33 mg/kg/day, however, four of six have
alternate day regimes. Similarly, Pandya et al., 2005, evaluated
30 patients for a 10-year follow up and found that prednisone
dose was decreased to a mean dose of 0.36 mg/kg/day [7].
1.2. Exercise
Most adults with DMD have very limited motor abilities.
However, some upper extremity muscles, especially finger
flexors, may be well preserved and afford the patient the
important abilities to control a motorized wheelchair joystick,
play electronic games and use the computer keyboard.
Physiotherapy should concentrate on stretching the upper
extremity muscles to minimize contractures. A daily stretching
routine should include elbow flexors, forearm pronators, wrist
flexors, and long finger flexors [8]. Stretching of the lower
extremities, (hip flexors, knee flexors and foot plantar flexors)
should also continue past the period of ambulation and into
adulthood as this provides relief from symptoms of stiffness and
improves pain. In addition to stretching, patients benefit from
therapy in the pool with assistance and support of the head and
neck, where the buoyancy provides a degree of freedom of
movement.
2. Cardiac management
As supportive care for individuals with DMD leads to greater
longevity, both recognition and treatment of cardiac manifesta-
tions are increasingly important. Prior to the development of
noninvasive methods to assess cardiac function, the incidence
of myocardial dysfunction among those with DMDwas thought
to be low, but cardiomyopathy was often seen on autopsy [9].
Today, detection of asymptomatic left ventricular dysfunction
and arrhythmia allows early and potentially life-saving treat-
ment. In our practice, screening for anticipated cardiomyopathy
is routine and co-incident with the diagnosis of DMD.
2.1. Incidence of dilated cardiomyopathy (DCM)
In addition to its role in skeletal muscle, dystrophin plays an
essential role in stabilizing the cytoskeletal complex within
cardiac myocytes. Alterations in several components of this
complex are associated with DCM (with or without associated
skeletal myopathy), including delta-sarcoglycan, desmin, and
metavinculin [10–12]. Despite consistent absence of dystro-
phin, however, the cardiac phenotype among DMD patients
varies from no discernible left ventricular (LV) enlargement or
dysfunction to early onset DCM with heart failure. The overall
incidence of DCM in DMD has been estimated to be 25% by 6
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all people with DMD have cardiac involvement [13,14]. As
cardiomyopathy is an age-dependent disorder to which all
DMD patients are genetically predisposed, there is a high
likelihood of cardiac dysfunction over an affected individual's
lifetime. Frequently, significant cardiac abnormalities predate
symptoms [9,13]. Accordingly, serial noninvasive assessment
of cardiac dysfunction and early therapeutic intervention is
strongly recommended.
Risk factors associated with the onset and severity of DCM
are not clear. Severity of cardiomyopathy is not directly
proportional to skeletal muscle strength, as has frequently
been observed in Becker muscular dystrophy (BMD) patients
who have nearly normal limb strength and receive cardiac
transplantation for cardiomyopathy. Recently, there has been a
suggestion that the deletion location may be linked to DCM.
Jefferies and colleagues recently reported that in 47 individuals
with DMD or BMD there was a higher incidence of DCM in
those with a deletion occurring in exons encoding the N-terminal
portion of dystrophin, and lower incidence of DCM in those with
deletions occurring in exons encoding the C-terminus of
dystrophin [15]. Data from additional subjects and follow-up
of these initial individuals will be important to further evaluate
this possibility, which could be an important tool in predicting
cardiomyopathy.
2.2. Methods of detecting DCM
Scoliosis, positive-pressure ventilation, and flexion contrac-
tures may all contribute to difficulties in obtaining reliable data
from cardiac imaging, and each of these factors should be taken
into account when considering the best method of determining
cardiac size and function. Options include echocardiography,
magnetic resonance imaging (MRI), and multiple gated
acquisition scan (MUGA). Additional methods, such as serum
B-natriuretic peptide (BNP) or noninvasive impedance cardio-
graphy, may be useful, but at this point, there is not sufficient
data to support their routine use in this population instead of
more traditional techniques. Electrocardiography (ECG) is
useful for determination of cardiac arrhythmia, but lacks both
sensitivity and specificity in assessment of structural cardiac
disease. A normal ECG does not provide adequate evidence of
normal cardiac size or function, and an abnormal ECG provides
no quantification of cardiac dysfunction (if present). In our
practice, we perform ECGs when there is concern for
arrhythmias such as atrial fibrillation, supraventricular tachy-
cardia, or heart block (which is less common). We do not
routinely perform surveillance ECGs for evidence of cardiac
enlargement or dysfunction, as their yield is relatively low in
comparison to echocardiography.
Echocardiography allows determination of the left ventri-
cular (LV) size, wall thickness, valve function, as well as both
LV systolic and diastolic function. While it may be technically
limited in some patients with DMD, the use of intravenous
echocardiographic contrast agents may improve its accuracy
and feasibility. As opposed to some other methods of cardiac
imaging, echocardiograms can be done while the patientremains in a wheelchair, which is a significant benefit to
advanced patients with poor pulmonary function and hip
contractures. While interpretation of the ejection fraction can
vary among qualified readers, methods used to quantify cardiac
performance may limit such variability [16]. In addition, factors
such as intercurrent illness or respiratory insufficiency may be
taken into account during interpretation of the study.
Cardiac MRI provides one of the most accurate assessments
of LV size and function, and also adds the ability to image focal
myocardial scarring. However, it is necessary to gate images
such that data are not indiscriminately acquired throughout the
cardiac cycle. Cine-MRI can be accomplished by compiling
multiple images from evenly spaced phases of the cardiac cycle
in a cinematic display. Limitations of cardiac MRI include the
ease with which motion results in artifact, high cost, and
technical factors related to acquisition of images in a narrow
compartment for individuals with DMD.
MUGA scanning is performed by radiolabeling red blood
cells, then measuring the activity of the radiotracer inside the
cardiac chambers in systole and diastole through an external
camera. It is one of the most accurate and reproducible methods
of determining LVejection fraction [17]. However, this method
is limited in its ability to provide information about LV wall
thickness or cardiac valve performance. As with cardiac MRI,
limitations related to patient immobility may make this
technique less desirable for some individuals.
The consensus statement from the 107th ENMC Interna-
tional Workshop recommends that DMD patients have an
echocardiogram and ECG at diagnosis, every 2 years to age ten,
and annually after age ten [18]. In our adult DMD practice we
use echocardiograms yearly until cardiomyopathy is identified,
and subsequently if there is a change in clinical status, such as
worsening symptoms or arrhythmia, or if the results of the
repeat echocardiogram are likely to change management. This
practice is in accordance with published guidelines for all forms
of dilated cardiomyopathy [19]. Although echocardiography
may be less sensitive than MRI for determination of cardiac size
and function, we find that it has significant advantages of cost
and convenience for DMD patients. Our hope is that additional
research will determine the role of advanced cardiac imaging
techniques in this population.
2.3. Cardiac arrhythmia
Both bradycardic and tachycardic arrhythmias can occur in
DMD. Sinus tachycardia is the most common cardiac
arrhythmia associated with DMD. Possible mechanisms con-
tributing to resting tachycardia seen among adults with DMD
include profound deconditioning, adrenergic stimulation, or
reactive increase in heart rate in response to poor cardiac
function.
The risk of life-threatening ventricular arrhythmia is
increased for patients with low ejection fraction, as has been
noted for DCM of any cause [20]. Attempts to identify
electrocardiographic indications of increased risk have also
been performed. Among 84 individuals with DMD age 18.6±
4.8 years, Corrado and colleagues reported no additional
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graphy, or 24-h Holter telemetry monitoring [21]. In contrast,
QT dispersion is a marker of myocardial electrical instability,
and when increased, is an indication of elevation in risk of
ventricular arrhythmia [22]. Yotsukura and colleagues per-
formed QT variability testing in 67 people with DMD, average
age 20.5±4.7 years, and showed that increased QT dispersion is
a marker of ventricular arrhythmia in this population [23].
Implantable cardio-defibrillators (ICDs) are becoming more
widely used for patients at highest risk of fatal or life-
threatening ventricular arrhythmias. However, receipt of an
ICD remains a very personal decision for those at risk of life-
threatening ventricular arrhythmia. While many people with
DMD meet the current standard in the United States of
qualifying for an ICD on the basis of an ejection fraction less
than 35%, published guidelines discourage use of ICDs for
people with untreatable terminal illness or life-expectancy less
than 6 months despite ICD placement [24]. Furthermore, use of
standard medications described below can improve the ejection
fraction and decrease the risk of ventricular arrhythmia.
Prior to consideration of an ICD, it is our practice to use
medical therapy to both improve cardiac function and decrease
risk of arrhythmia. If medications are not successful in
improving the ejection fraction to greater than 35%, or if
symptomatic ventricular arrhythmia (syncope or presyncope)
occurs, then risks and benefits of ICD are considered and
discussed in detail with the patient and family. This is a difficult
topic for adolescents and young adults, though for those at
greatest risk of life-threatening cardiac arrhythmia, it can be
quite successful at prolonging life [25,26]. The risks of
psychological harm, inappropriate firing, and procedural
complications of ICDs should be carefully considered in
relation to the risk of sudden arrhythmic death for any patient
considering an ICD. Of 23 adult DMD patients in our practice,
one has received ICD and several are considering this therapy.
2.4. Treatments for cardiac complications
In the absence of large clinical trials with adult DMD patients
who have DCM, medical therapy is derived from multiple large
clinical trials which enrolled varied groups of patients,
including ischemic, valvular, genetic, and acquired forms of
DCM. In these populations, clear benefits have been demon-
strated with several therapies regardless of the etiology of
DCM, making it a reasonable extension to use these medica-
tions in a population affected with DMD. Smaller clinical trials
noted below have assessed treatment for patients with DMD
more specifically.
Use of angiotensin converting enzyme inhibitors (ACEi) is
based on several large, well designed, prospective trials that
show improved survival and decreased symptoms with this
therapy for patients with DCM. The CONSENSUS-1 trial
reported a 40% reduction in mortality at 6 months in patients
with severe heart failure when treated with enalapril versus
placebo, in addition to standard therapy [27]. Similarly, in a
cohort of less symptomatic patients with DCM, the SOLVD trial
showed 16% reduction in mortality with enalapril treatmentcompared to placebo [28]. The SAVE trial randomized patients
with recent myocardial infarction and ejection fraction less than
40%, but notably without symptoms of heart failure, to receive
either captopril or placebo [29]. During the follow-up period of
42 months, those treated with captopril had both improvement
in survival and reduced morbidity and mortality due to major
cardiovascular events.
As a class, ACEi are associated with side effects, including
cough and angioedema. Because of this, studies testing the
comparative benefits of angiotensin II-type 1 receptor blockers
(ARBs) in DCM have been performed. ARBs appear to have
lower incidence of side effects and similar effects on reduction
in mortality as compared to ACEi [30,31].
Duboc and colleagues recently reported their analysis of
ACEi prior to onset of LV dysfunction in patients with DMD
[32]. They enrolled 57 people age 9.5 to 13 years with DMD
and normal cardiac function to receive an ACEi (perindopril) or
placebo in a double-blinded fashion. After 3 years, all
participants received open-label ACEi and were followed for
2 more years. After 3 years there was no difference in cardiac
function in the 2 groups. However, after 5 years, there were 8
people with ejection fraction less than 45% in the placebo group
compared to 1 person in the ACEi-treated group ( p=0.02).
Based on these results, the study authors suggest starting all
patients with DMD on ACEi as early as 9 years age. By the time
an individual with DMD is seen in our adult DMD program, if
not already started on ACEi or ARB by our pediatric collegues,
it is our practice to do so even if cardiac function is normal or
nearly normal.
Similar to ACEi and ARB, there are many studies supporting
use of beta-adrenergic receptor blockers in people with
symptomatic DCM regardless of the etiology [33–36]. This
class of medications provides not only anti-arrhythmic therapy,
but also improves ejection fraction and adverse ventricular
remodeling [37]. In our practice, use of beta-blockade is
standard for those with symptomatic heart failure and is added
after ACEi or ARB for individuals with persistent asympto-
matic LV dysfunction (ejection fraction less than 40%).
For DMD patients with symptomatic heart failure, several
additional medications are likely to provide symptomatic
benefit and perhaps improvement in survival. In such cases,
use of medications such as spironolactone, loop diuretics, and
digoxin should be considered. The use of warfarin antic-
oagulation has been studied in several trials of dilated
cardiomyopathy, and to date, has only been shown to be of
benefit in the setting of concomitant atrial fibrillation, recent
anterior transmural myocardial infarction, or upon demonstra-
tion of an intracardiac thrombus [38,39]. We do not empirically
treat our DMD patients with warfarin in the absence of a clear
indication for its use other than low ejection fraction.
2.5. Emerging cardiac therapy
Yasuda and colleagues recently reported work performed in a
murine model of DMD, the mdx mouse [40]. In dystrophin-
deficient cardiomyocytes, they showed reduced compliance and
increased susceptibility to stretch-mediated calcium overload.
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of membrane integrity, they treated dystrophin-deficient mice
with poloxamer 188, a compound previously shown to insert
into artificial lipid monolayers and repair damaged biological
membranes [41]. Remarkably, functional deficits in dystrophin-
deficient cardiomyocytes were repaired by intravenous infusion
of poloxamer 188, suggesting that membrane stabilizing
therapies may be an rational therapy for DMD based on
molecular dissection of disease pathogenesis [40].
Future trials investigating emerging therapies for more
common forms of dilated cardiomyopathy such as calcium
sensitizers, passive cardiac restraint devices, and other neuro-
hormonal modulators, may identify improved therapies for this
condition. In addition, there is an urgent need for targeted
clinical studies of both pathogenesis and therapy of cardiomyo-
pathy in dystrophinopathy patients.
3. Pulmonary management
The majority of individuals with DMD eventually die from
complications of respiratory muscle weakness [42]. This
includes progressive restrictive ventilatory defects, chronic
hypoventilation, and pulmonary infections [43]. As most people
with DMD begin to develop respiratory muscle weakness in the
second decade of life, nearly all adults will have respiratory
compromise. The following section will briefly review
respiratory muscle involvement in DMD, the evaluation and
treatment of neuromuscular respiratory complications.
The principal muscles for inspiration are the diaphragm and
external intercostals. These are assisted by the accessory
muscles of respiration, the sternocleidomastoid and scalenes
[44]. While expiration during quiet breathing is a passive act,
forced expiration and coughing require use of the expiratory
muscles including the internal intercostals and the abdominal
wall muscles. When inspiratory muscle weakness begins,
patients are able to increase their respiratory frequency and
maintain adequate ventilation. However, as weakness pro-
gresses patients hypoventilate which results in elevated arterial
CO2 and hypoxemia. Weakness of expiratory muscles results in
decreased speech volume and more importantly, inability to
cough forcefully enough to clear airway secretions. This places
patients at increased risk of pneumonia.
3.1. Respiratory evaluation
Patients with DMD are generally wheelchair bound before
they develop significant respiratory muscle weakness. After age
10 to 14, patients gradually begin to lose respiratory muscle
function. Estimates of the rate of loss vary from 0.04 L/year to
0.74 L/year or 2% to 39% predicted per year. The median loss in
vital capacity is estimated to be 8.0% predicted per year [45,46].
Because the loss of respiratory function is very gradual and
patients have severe arm and leg weakness prior to respiratory
muscle weakness, most patients have little shortness of breath
and few respiratory complaints. Therefore clinicians need to
perform routine respiratory evaluations in order to detect
progressive respiratory muscle weakness and impendingrespiratory complications. The American Thoracic Society's
consensus statement on DMD recommends evaluation by a
respiratory specialist twice a year after wheelchair confinement,
fall in Vital Capacity below 80%, or age 12 [42]. In our practice,
frequency of pulmonary follow-up is highly variable. Patients
who have stable respiratory issues may only need to be seen
annually, while other patients may need to be seen multiple
times in a year.
Evaluation should include a thorough history including
questions regarding dyspnea, orthopnea, cough, difficulty with
secretions, swallowing problems and sleep characteristics. Lying
supine places the diaphragm at a mechanical disadvantage, and
puts additional loads on the diaphragm from redistribution of
blood into the pulmonary vasculature and shifting the abdominal
contents against the diaphragm [47]. As a result, patients with
DMD may note orthopnea or may complain of difficulty
sleeping. Hypoventilation is often more pronounced at night and
can result in nocturnal hypercapnia, elevation of the arterial
partial pressure of carbon dioxide, which can cause morning
headaches.
Objective measures of respiratory function are important for
prognosis and timing respiratory interventions. There is some
debate regarding the optimal tests for individuals with DMD but
spirometry is the most standardized, best studied single test to
obtain. Spirometry measures the forced vital capacity (FVC)
and forced expiratory volume in 1 s (FEV1). The forced vital
capacity is the volume of air expired from a full inspiration to a
full exhalation. Other useful testing includes maximal inspira-
tory and expiratory mouth pressures, cough peak flow rates,
arterial blood gas measurement, end tidal CO2 (the measure-
ment of exhaled carbon dioxide, which should approximate
arterial CO2), oxygen saturation, and polysomnography. Cough
peak flow rates can be measured with a standard peak flow
meter attached to a tight sealing face mask [43]. Flow rates
below 160 L/min are felt to place individuals at high risk for
mucous plugging and respiratory insufficiency. Cough peak
flows fall during acute illness and a cough peak flow of
270 L/min can fall below 160 during an acute infection.
Therefore, many recommend initiating a series of pulmonary
interventions (see below) when cough peak flow rates reach
270 L/min [48]. Alveolar hypoventilation is defined by an
elevated arterial CO2. The best measure is obtained from
arterial puncture but this is painful and can be technically
difficult in adults with DMD due to limb contractures. Therefore
capnography, measurement of exhaled carbon dioxide, may be
an attractive alternative in these patients, though its use has not
been thoroughly evaluated in this patient population. Pulse
oximetry is a simple method to assess oxygenation. DMD
patients are at risk for mucous plugging and pneumonia, both of
which can cause abrupt declines in oxygen saturation. It has
been recommended that individuals with DMD and cough peak
flow ≤270 L/min be equipped with an oximeter at home to
monitor their oxygen saturation regularly. Hypoventilation,
atelectasis, or mucous plugging can result in oxygen desatura-
tion. Patients should be instructed to initiate assisted cough
techniques and assisted ventilation if their oxygen saturation
falls below 95% [48].
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sleeping well before it occurs during wakefulness. This can
occur simply from muscle weakness but may be complicated by
central or obstructive sleep apnea. The recommendations for
ordering sleep studies vary but the American Thoracic Society
Consensus statement recommends yearly polysomnography
[42]. However, overnight studies in a sleep laboratory can be
challenging for DMD patients due to problems with positioning
and mobility. In our practice, we consider polysomnography if
there are symptoms of sleep disturbance that may be respiratory
in origin and daytime values for CO2, O2 and FVC do not
warrant ventilatory support If patients have daytime hypercap-
nia, oxygen desaturation or a sufficiently low forced vital
capacity, we initiate noninvasive ventilation without a sleep
study.
Another crucial element of the pulmonary evaluation of
individuals with DMD is discussion of advanced directives and
attitudes regarding long term mechanical ventilation. Patients
should understand the natural progression of DMD and should
have ample opportunity to explore and learn about the various
treatment options available. To this end, it can be helpful for
patients to speak to other patients who have undergone
tracheostomy and learn from their experiences.
3.2. Respiratory interventions/treatments
Noninvasive positive pressure ventilators (NPPV) are
devices that force air into the lungs via a mask or mouthpiece
rather than an endotracheal tube or tracheostomy tube. The most
common NPPV devices in use today are bilevel pressure cycled
units in which separate inspiratory and expiratory pressures are
set. The level of positive pressure support delivered to the
patient is the difference between the inspiratory and expiratory
pressure. Many patients with DMD have central sleep apnea and
require NPPV machines that allow a respiratory rate to be set.
As respiratory muscle weakness becomes more pronounced
increasing levels of support are needed. Volume cycled
ventilators, which are ventilators that deliver a preset tidal
volume rather than a set pressure, may be able to provide more
support than bilevel pressure cycled ventilators. Some practi-
tioners favor these over bilevel pressure ventilators as
respiratory muscle weakness progresses. Because nocturnal
hypoventilation occurs before daytime hypoventilation, most
patients initially use NPPV during the night and eventually shift
toward daytime use as well. During daytime use, a mouthpiece
can be a particularly convenient interface. Ventilators can be
attached to wheelchairs and mouthpieces can be attached in
place next to the patient's mouth. This allows patients to take
breaths from the ventilator when needed but does not interfere
with eating or speaking. The criteria to initiate ventilatory
support are not well defined in DMD. One clear cut indication
to initiate NPPV is evidence of hypercapnia or hypoxemia
during sleep or wakefulness. Some advocate initiating NPPV
when the cough peak flow falls below 270 L/min. While an
optimal value of FVC indicating the need for NPPV has not
been determined, most health care insurers in the United States
reimburse NPPV units for restrictive ventilatory defects due torespiratory muscle weakness when the FVC falls below 50%
predicted.
Though randomized trials of NPPV in DMD are lacking,
there are observational studies showing benefits. Noninvasive
ventilation has been shown to improve hypercarbia, hypoxemia
[49,50], survival [1], and quality of life [50], and may delay
decline in lung function [51].
Some advocates of noninvasive approaches to respiratory
care in DMD, such as discussed above, argue that no DMD
patients ever require tracheostomy [52,53] and that quality of
life is better and complications are fewer when patients are
managed noninvasively [54]. Nevertheless, this view is not
universally accepted. Some patients find it easier to eat, drink,
and speak with a tracheostomy than with various oral and nasal
interfaces. Furthermore, there is concern that once a patient
requires 24 h ventilatory support, noninvasive ventilation is not
as secure as a permanent tracheostomy. However, there are also
disadvantages to tracheostomy. It requires surgery and the risks
of anesthesia which are increased in this population. It requires
hospitalization and is painful during the perioperative period
and many patients have more pulmonary secretions shortly after
having a tracheostomy tube placed. One of the more difficult
factors to invasive mechanical ventilation is it requires that a
caregiver be present 24 h per day. Nursing support is not well
covered by most insurance plans in the United States and this
places both financial and emotional strains on families.
Decreased mobility and weakened cough place DMD
patients at increased risk of complications from pulmonary
infections. While there is no data regarding vaccination in this
patient population, it is prudent to recommend pneumoccocal
vaccination every 5 years and annual influenza vaccination.
Another important pulmonary intervention is assisted
coughing. While manually assisted coughing can be of help,
mechanical insufflation–exsufflation has been proven to
produce greater cough velocities. Mechanical insufflation–
exsufflation is also known as cough-assist™, or an in-
exsufflator. It is a device that delivers a high positive pressure
through a mask, mouthpiece, or tracheostomy, which inflates
the lungs. Then, either manually or automatically it rapidly
cycles to a negative pressure mode and sucks air from the lungs.
This effectively simulates a natural cough and has been shown
to generate high expiratory air flow. Studies have documented
flows as high as 4.1 L/s [55]. In order to prevent infections and
mucous plugging, mechanical insufflation–exsufflation should
be initiated when the cough peak flow falls below 270 L/min
and should be used at least twice daily. Combining oxygen
saturation monitoring, with NPPVand mechanical insufflation–
exsufflation has been shown to reduce morbidity and mortality
in DMD [48].
In 23 adult DMD patients cared for in our multidisciplinary
clinic, six (26%) of patients are unable to perform pulmonary
function tests. In those who can perform spirometry, the mean
vital capacity is 1.22 L or 29% predicted. Ten (43%) of subjects
currently use or have used noninvasive ventilation in the past
and six (26%) of patients have tracheostomy tubes.
Respiratory care for patients with DMD has improved
dramatically over the last 15 years. As a result both quality of
235K.R. Wagner et al. / Biochimica et Biophysica Acta 1772 (2007) 229–237life and survival have increased markedly. Patients with DMD
need to have regular evaluations by pulmonologists, and need to
be cared for by a multidisciplinary team that is fully familiar
with noninvasive monitoring, ventilation, and assisted cough
techniques. In spite of improvements in care, there are
controversies regarding optimal methods for ventilation. These
include debates over volume cycled ventilators vs. bilevel
pressure ventilators, timing of ventilation and under what
circumstances tracheostomy should be recommended. Further
research will be crucial to resolve these clinical dilemmas.
4. Other medical issues
4.1. Orthopedic concerns
Osteoporosis is a major problem in adults with DMD. This
apparently occurs primarily from decreased weight bearing with
loss of ambulation but may be accentuated by long term
prednisone use. Fractures, particularly of the lower limbs, occur
during routine daily care, including transfers, physical therapy
and dressing and are estimated in one study to occur in as many
as 30% of wheelchair-dependent DMD patients [56]. Wheel-
chair-dependent patients may have less exposure to sunlight and
have low Vitamin D levels. For these reasons, we routinely treat
all our adult patients, with daily calcium carbonate plus Vitamin
D as well as weekly alendronate to decrease bone resorption.
Scoliosis affects most patients with DMD and contributes to
respiratory function compromise, pain and deformity. The
decision to have surgical fixation of the spine is usually made in
early adolescence and adults rarely have the orthopedic or
cardiopulmonary criteria to consider surgery. Sixty percent of
our adults DMD patients (14 of 23) had scoliosis surgery in
adolescence and there was no correlation between adult FVC in
those that had received surgery (mean=19% of predicted) and
those that had not (mean=22% of predicted). The emphasis in
managing spinal deformity in adult patients is rather on proper
seating. Proper wheelchair fitting and adjustments are critical to
slow deformities, maintain mobility and enhance quality of life
[8,57].
4.2. Gastrointestinal and urinary concerns
Gastrointestinal symptoms may be under treated in this
patient population. Nonambulatory DMD patients are more
likely to suffer gastroesophageal reflux and esophagitis due to
involvement of pharyngeal and hypopharyngeal musculature
than healthy peers or ambulatory DMD patients [58].
Constipation due to lack of ambulation and smooth muscle
hypomotility may decrease lung volumes and coughing force. It
is important that the neurologist ask about these symptoms
which in many cases, can be simply treated. Proton pump
inhibitors are very effective in treating reflux with very rare side
effects. Good hydration, balanced dietary intake, docusate
sodium (stool softener) and senna (a promotility agent) are
recommended to prevent severe constipation. On rare occa-
sions, acute gastric dilation occurs with or without acidosis.
This is a potentially life-threatening condition but, if recog-nized, responds well to prokinetic agents, nasogastric tube
decompression of gastric contents and intravenous fluids.
Urinary symptoms are common in both children and adults
with DMD [62]. Many have urinary urgency and some have
difficulty with daytime and/or nocturnal continence. Urinary
symptoms should be evaluated by urodynamics, bladder
ultrasound and urine microscopic analysis and culture as
appropriate. Many will be aided by the use of anticholinergics
such as oxybutynin [62]. Alternatively, a penile sheath attached
to a collection bag may be used for urgency or incontinence and
may be convenient for those who are away from home for any
length of time.
5. Social issues
Avariety of social issues are becoming more apparent as the
adult DMD population grows. These issues are at least as
important as the physical ones described above and include the
need for quality care, personal independence, educational and
employment opportunities, meaningful relationships and sexual
activity. The ability to find and obtain practical aids is often
difficult [2] and can be aided by occupational therapists and care
coordinators. A social worker is also an integral part of the
multidisciplinary team. Social issues should be discussed with
patients, solutions sought and potential side effects, such as
depression, treated. Thirty percent of patients in our adult DMD
clinic (7 of 23) are receiving treatment for depression with
selective serotonin reuptake inhibitors (SSRIs). However,
despite physical limitations, several studies demonstrate that
adults with DMD perceive a high quality of life, one that is
underestimated by health care professionals [59–61].
6. Conclusion
A variety of changes in multidisciplinary care have
contributed to children with DMD surviving well into
adulthood. This number of adults with DMD is likely to grow
substantially from continued changes in practice such as early
and prolonged use of steroids, nocturnal ventilation and ACE
inhibitors. In addition, future therapies discussed in this issue
including gene and cell based therapies, as well as efforts to
increase muscle growth and regeneration, will not necessarily
cure but attenuate the disease and further increase the number of
DMD adults. The collective clinical experience caring for this
population is still small, and data sparse. It will be important to
learn from these young men as we care for them.
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